StreetInsider.com News Articles

Rani Therapeutics to Participate in the Chardan Healthcare Conference

Tue, 13 Oct 2026 16:05:00 -0400

SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below:

Chardan Healthcare Conference

Date: Tuesday, October 20, 2026 at 1:00pm E.T.
Location: New York, New York
Presenter: Chief Executive Officer, Talat Imran, Chief Financial Officer, Nicholas Maestas, and Chief Business Officer, Kate McKinley
Format: Fireside Chat and 1x1 Meetings

Interested parties can access the live webcast for this conference from the Investor

Rani Therapeutics to Participate in the Chardan Healthcare Conference

Tue, 13 Oct 2026 16:05:00 -0400

Chardan Healthcare Conference

Interested parties can access the live webcast for this conference from the Investor

H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)

Tue, 06 Oct 2026 07:07:18 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Rani Therapeutics (NASDAQ: RANI).

The analyst commented: "RANI has announced that the RaniPill platform has been accepted into the FDA’s Emerging Technology Program (ETP), which we view as a positive given the opportunity for substantive engagement with FDA around the manufacturing, CMC and quality considerations associated with the platform. We believe RANI now has a formal mechanism specifically designed to identify and understand the regulatory requirements for the RaniPill, creating a path to convert regulatory dialogue into a more clearly defined set of FDA requirements, with management

FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program

Mon, 05 Oct 2026 08:04:23 -0400

Rani Therapeutics Holdings (Nasdaq: RANI) announced that its RaniPill Capsule platform technology has been accepted into the U.S. Food and Drug Administration's Emerging Technology Program (ETP), according to a company press release.

The ETP, administered by the FDA's Center for Drug Evaluation and Research, is designed to support the development of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate potential to improve pharmaceutical product quality and incorporate novel elements for which the FDA has limited review or inspection experience.

Participation gives Rani Therapeutics early, direct engagement with the FDA's Emerging Technology Team through pre-submission meetings

FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program

Mon, 05 Oct 2026 08:04:23 -0400

Participation gives Rani Therapeutics early, direct engagement with the FDA's Emerging Technology Team through pre-submission meetings

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Mon, 05 Oct 2026 08:00:00 -0400

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP).

The FDA’s Emerging Technology Program, administered within the Agency’s Center for Drug Evaluation and Research (CDER), is designed to support the development and implementation of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate the potential to improve pharmaceutical product quality

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Mon, 05 Oct 2026 08:00:00 -0400

Form 4 Rani Therapeutics Holdin For: Sep 27 Filed by: Imran Talat

Tue, 29 Sep 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260929/27123087.html

Form 4 Rani Therapeutics Holdin For: Sep 27 Filed by: Javadi Alireza

Tue, 29 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260929/27123005.html

H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)

Fri, 21 Aug 2026 06:59:31 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Rani Therapeutics (NASDAQ: RANI).

The analyst commented: "The quarter was financially clean, with EPS of $(0.04) ahead of FactSet’s $(0.05), R&D expense of $5.0M below FactSet’s $5.5M, and $53.4M of cash and marketable securities at quarter-end. More important for the stock, RANI has now dosed the first participants in the RT-114 Phase 1a expansion cohort, expects additional data by YE26 and continues to target initiation of the eight-week Phase 1b obesity study by YE26, with data expected in 2027. Following the >150% relative bioavailability achieved with a

Chardan Starts Rani Therapeutics (RANI) at Buy

Tue, 18 Aug 2026 07:12:23 -0400

Chardan analyst Andreas Argyrides initiates coverage on Rani Therapeutics (NASDAQ: RANI) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Rani Therapeutics click here. For more ratings news on Rani Therapeutics click here.

Shares of Rani Therapeutics closed at $0.80 yesterday.

Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932196.html

Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932196.html

Form 10-Q Rani Therapeutics Holdin For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921446.html

Form 10-Q Rani Therapeutics Holdin For: Jun 30

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921446.html

Rani Therapeutics Holdings, Inc. (RANI) Tops Q2 EPS by 1c

Thu, 13 Aug 2026 16:15:47 -0400

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Rani Therapeutics Holdings, Inc. (RANI) click here.

Form 8-K Rani Therapeutics Holdin For: Aug 13

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921150.html

Form 8-K Rani Therapeutics Holdin For: Aug 13

Thu, 13 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260813/26921150.html

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Thu, 13 Aug 2026 16:05:00 -0400

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~

~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~

~ Completed a $20 million registered direct offering ~

~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~

~ Appointed Nicholas Maestas